SNCA and Parkinson disease: The use of these engineered EVs led to the effective silencing of BACE1, an approach that has therapeutic promise in AD (Alvarez-Erviti et al., 2011b), or silencing of α-synuclein, which reduced the formation of intracellular inclusions in an in vivo model of PD (Cooper et al., 2014).